Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing

Cellino aims to significantly expand patient access to stem cell-based therapies with autonomous end-to-end manufacturing / Proceeds will expand machine learning, software, and hardware capabilities and to develop early-stage Good Manufacturing Practice (GMP) capabilities to support clinical trials, with plans to build the first autonomous human cell foundry in 2025 / Investment further strengthens existing company portfolio of Leaps by Bayer in the fields of cell and gene therapies

Cambridge, MA, US and Leverkusen, Germany / January 25, 2022 – Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG – Leaps by Bayer – 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining existing investors The Engine and Khosla Ventures. The company has raised a total of $96 million i